Work

71P Pre- and post-polyphenol intake and ovarian cancer survival: Evidence from a prospective cohort study

Year: 2024

Type: article

Abstract: SD 11.1).Use of Cb+T+Bev was 40.1% (335/835) overall, 43.8% (205/468) for patients with complete gross resection, 38.7% (70/181) for patients with 1cm residual disease, and 32.3% (60/186) for patients with >1cm residual disease.Cb+T+Bev was not associated with improved OS (HR 0.88, 95% CI 0.73-1.07,P¼0.216) or PFS (HR 0.95, 95% CI 0.79-1.10,P¼0.610).Also in the subgroup of patients with >1cm residual disease, Cb+T+Bev was not associated with improved OS (HR 0.90, 95% CI 0.61-1.31,P¼0.565) or PFS (HR 0.86, P¼0.483).Conclusions: This data suggests that bevacizumab is often used for patients with primary FIGO stage IIIB to IV EOC undergoing PDS although it does not provide an OS or PFS benefit.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2024.103578

Authors: J-N. Sun, Q-J. Wu, T-T. Gong, Y. Li

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,730

Funders: National Natural Science Foundation of China, China Medical University, National Key Research and Development Program of China, Shengjing Hospital